Low risk patients
Brief (<7d duration) of<unk>  with few comorbidities
Consider discharge it patient scores ≥21 using the MASCC risk index scoring system
Score ≥21 associated with <5% risk for<unk> e complications and mortality <1%
Brief (<7d duration) of<unk>  with few comorbidities
Consider discharge it patient scores ≥21 using the MASCC risk index scoring system
Score ≥21 associated with <5% risk for<unk> e complications and mortality <1%
The MASCC study was an international collaboration to derive and validate a scoring system to identify low-risk patients for complications of febrile<unk> .
No or Mild Symptoms
Moderate Symptoms<unk> e Symptoms
5
3
0
Clinical Index of Stable febrile<unk> 
230 febrile<unk> , chemo-therapy induced, retrospective analysis of MASCC vs. CISNE
MASCC was ~55% specific and CISNE was ~98% specific with PPV ~98%
MASCC was ~55% specific and CISNE was ~98% specific with PPV ~98%
Neutropenic fever
Transfusion reaction
Acute fever
Medication allergies and toxicities
Fever and rash
Tumor-related fever
Erythematous rash
Malignant airway obstruction